Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 120221-14-9 | MDL No. : | MFCD00037475 |
Formula : | C12H14ClNO8 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | PJCVBKZRKNFZOD-RMPHRYRLSA-N |
M.W : | 335.69 | Pubchem ID : | 18651654 |
Synonyms : |
|
Num. heavy atoms : | 22 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.5 |
Num. rotatable bonds : | 4 |
Num. H-bond acceptors : | 8.0 |
Num. H-bond donors : | 4.0 |
Molar Refractivity : | 74.42 |
TPSA : | 145.2 Ų |
GI absorption : | Low |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -8.26 cm/s |
Log Po/w (iLOGP) : | 1.1 |
Log Po/w (XLOGP3) : | 0.12 |
Log Po/w (WLOGP) : | -0.57 |
Log Po/w (MLOGP) : | -1.32 |
Log Po/w (SILICOS-IT) : | -2.22 |
Consensus Log Po/w : | -0.58 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 1.0 |
Egan : | 1.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.93 |
Solubility : | 3.9 mg/ml ; 0.0116 mol/l |
Class : | Very soluble |
Log S (Ali) : | -2.72 |
Solubility : | 0.632 mg/ml ; 0.00188 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -0.18 |
Solubility : | 219.0 mg/ml ; 0.653 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 2.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 4.21 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
40% | With ammonia; In methanol; at 20.0℃; | General procedure: Typically, the peracetylated aryl glycopyranosides 12 were suspended in 12-15mL 7M ammonia in methanol and stirred at ambient temperature. After 5-24h, all volatile material was evaporated. The resulting residue was recrystallized from ethyl acetate or purified by column chromatography on silica gel as noted yielding the target compounds [26]. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With camphor-10-sulfonic acid; at 20.0℃; for 2.0h; | The synthesis was performed according to a general protocol for related compounds [56]. Benzaldehyde dimethyl acetal (0.43g, 2.799mmol, 1.25equiv.) and camphorsulfonic acid (0.10g, 0.431mmol, 0.14equiv.) were added to the solution of 11f (0.75g, 2.239mmol) in 15mL acetonitrile at ambient temperature. After 2h, the solution was neutralized with 0.3mL trimethylamine, concentrated to yield a residue that was purified by column chromatography over silica gel (hexane/ethyl acetate=4/1-1/1, v/v) to give 17 (0.82g, 1.953mmol, 87%) as a colorless solid; Rf 0.17 (SiO2, cyclohexane/ethyl acetate=2/1, v/v); mp 222-224C; deltaH (CD3OD) 8.33 (d, 2.8, 1H), 8.20 (dd, 9.0, 2.8, 1H), 7.49-7.56 (m, 2H), 7.46 (d, 9.3, 1H), 7.31-7.40 (m, 2H), 5.62 (s, 1H), 5.34 (d, 7.8, 1H), 4.33 (dd, 9.8, 4.5, 1H), 3.66-3.84 (m, 4H), 3.61 (t, 9.2, 1H); deltaC (CD3OD) 159.1, 143.8, 139.0, 130.0, 129.1, 127.5, 126.8, 124.9, 124.9, 116.8, 103.0, 102.1, 81.7, 75.4, 74.7, 69.4, 67.9; HRMS, ESI-TOF+ m/z calcd. for C19H18ClNNaO8 [M+Na]+: 446.0619; found 446.0622. |